Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
In BriefThis Month in JNM

This Month in JNM

Journal of Nuclear Medicine February 2018, 59 (2) 8A;
  • Article
  • Info & Metrics
  • PDF
Loading

Selective tau imaging: Villemagne provides a brief review of the history of tau imaging and associated tracers and the ways in which they are expanding insight into the pathology of Alzheimer disease and other neurodegenerative conditions.

Page 175

PSMA targeting and the urology POV: Donin and Reiter offer an overview of prostate-specific membrane antigen targeting, with a focus on new PET and SPECT imaging tracers, therapeutic applications, and the outlook for future clinical use.

Page 177

Tumor microenvironment imaging: Helfen and colleagues describe the current status of and future outlook for in vivo molecular imaging of tumor immune components to explore cross-talk between tumor cells and the immune system.

Page 183

Responsible radiomics research: Vallières and colleagues present guidelines intended to improve the reporting and statistical qualities and resulting reproducibility of computer-aided diagnosis techniques that characterize tumor phenotypes through extraction of high-dimensional, mineable imaging data.

Page 189

Early PET and GIST management: Farag and colleagues document changes in management based on early evaluation of response on 18F-FDG PET in patients with gastrointestinal stromal tumors treated with neoadjuvant imatinib.

Page 194

18F-4FMFES vs. 18F-FES: Paquette and colleagues compare in a phase II trial the diagnostic potentials of PET imaging with the novel radiotracer 18F-4FMFES and with 18F-FES in patients with estrogen receptor–positive breast cancer.

Page 197

Adding SN biopsy in PCA assessment: Grivas and colleagues study biochemical recurrence after robot-assisted radical prostatectomy and extended pelvic lymph node dissection in prostate cancer patients, stratified by the application of sentinel node biopsy.

Page 204

Positron lymphography in murine melanoma: Lockau and colleagues explore whether metastatic nodes can be distinguished from normal nodes in mice by dynamic 18F-FDG lymphography, followed by resection under Cerenkov imaging guidance.

Page 210

Daratumumab bioconjugate PET/CT in multiple myeloma: Ghai and colleagues evaluate [89Zr]Zr-desferrioxamine-daratumumab, a high-affinity monoclonal antibody targeting CD38, in PET/CT imaging of multiple myeloma tumor models.

Page 216

LAR octreotide and 68Ga-DOTATATE uptake: Ayati and colleagues assess whether 68Ga-DOTATATE uptake on PET in normal tissues, primary tumor, and metastatic lesions before treatment with long-acting repeatable somatostatin analogs differs from that after treatment in individuals with neuroendocrine tumors.

Page 223

PSMA PET: Jadvar and Ballas offer perspective on the potentially transformational applications of prostate-specific membrane antigen imaging and therapy and preview a related article in this issue of JNM.

Page 228

PSMA-11 PET and salvage radiotherapy: Calais and colleagues use 68Ga-PSMA-11 PET/CT to map patterns of early biochemical recurrence after radical prostatectomy in patients with low prostate-specific antigen levels and compare the results with established practice guidelines.

Page 230

PET/CT validation of PSMA expression: Woythal and colleagues evaluate associations between intraprostatic 68Ga-PSMA PET/CT findings and prostate-specific membrane antigen expression on immunohistochemical staining to generate a cutoff value for differentiation between normal prostate and prostate cancer.

Page 238

Molecular RT with radionuclides: Baiu and colleagues test the therapeutic potential of a clinical-grade, 131I-labeled alkyl-phospholipid ether analog as a scaffold for tumor-targeted radiotherapy of pediatric malignancies.

Page 244

123I-MIBG HMR with CZT SPECT: Blaire and colleagues compare the heart-to-mediastinum ratio of 123I-MIBG uptake obtained using a dual-isotope multipinhole CZT camera technique with that using conventional planar imaging in patients with heart failure.

Page 251

Prognostic value of 123I-BMIPP SPECT: Hashimoto and colleagues explore the predictive value of SPECT-derived 123I-BMIPP defect scores in patients who have nonischemic heart failure with preserved ejection fraction.

Page 259

68Ga-pentixafor PET and plaque imaging: Weiberg and colleagues assess the prevalence, pattern, and clinical correlates of arterial wall accumulation of 68Ga-pentixafor, a specific CXC chemokine receptor 4 ligand for PET.

Page 266

PET quantification of MBF: Murthy and experts from the SNMMI and the American Society of Nuclear Cardiology consolidate and update technical considerations for clinical quantification of myocardial blood flow and flow reserve and review the scientific bases for clinical applications.

Page 273

15O-water PET in negative 99mTc-HMPAO SPECT: Acker and colleagues report on 15O-water PET with acetazolamide challenge findings in 18 patients in whom perfusion SPECT with acetazolamide challenge had been interpreted as showing no evidence of impaired cerebrovascular reserve capacity.

Page 294

Tau PET and MR correlations in AD: Nasrallah and colleagues determine whether 18F-flortaucipir PET, which targets tau aggregates, can differentiate nonamnestic from amnestic Alzheimer disease and compare results with MR imaging of gray matter atrophy.

Page 299

Quantification of 18F-DPA-714 PET data: Wimberley and colleagues present and test a compartmental model that accounts for the effect of endothelial translocator protein binding on quantification of 18F-DPA-714 PET scans from a cohort of healthy subjects.

Page 307

11C-HOMADAM PET test–retest: Adhikarla and colleagues measure the reliability of this PET agent with highly specific targeting, fast uptake kinetics, and negligible binding in the cerebellum in assessing serotonin transporter density imaging in healthy controls.

Page 315

68Ga-pentixafor PET/CT in bone infection: Bouter and colleagues determine in patients with suspected infection whether 68Ga-pentixafor, a CXC chemokine receptor 4 ligand,, is suitable for PET/CT imaging in chronic bone infection.

Page 320

LPA1 radiotracer for lung imaging: Gallezot and colleagues develop and evaluate an 11C-labeled radiotracer targeting the lysophosphatidic acid receptor type 1 and report on specific binding and quantification in the lungs of rhesus monkeys.

Page 327

68Ga-NOTA-UBI imaging of infection: Ebenhan and colleagues assess the cytotoxicity and radiation dosimetry of a functionalized antimicrobial peptide in in vitro and primate studies and perform first-in-human evaluations to diagnose infectious processes.

Page 334

Repebodies and EGFR imaging: Pyo and colleagues synthesize and study 3 64Cu-labeled anti–epidermal growth factor receptor repebodies—nonantibody protein scaffolds for tumor targeting that contain leucine-rich repeat modules—in cultured cells and tumor-bearing mice.

Page 340

  • © 2018 by the Society of Nuclear Medicine and Molecular Imaging.
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 59 (2)
Journal of Nuclear Medicine
Vol. 59, Issue 2
February 1, 2018
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
This Month in JNM
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
This Month in JNM
Journal of Nuclear Medicine Feb 2018, 59 (2) 8A;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
This Month in JNM
Journal of Nuclear Medicine Feb 2018, 59 (2) 8A;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • 64Cu-Labeled Repebody Molecules for Imaging of Epidermal Growth Factor Receptor–Expressing Tumors
  • Brain Perfusion Imaging Under Acetazolamide Challenge for Detection of Impaired Cerebrovascular Reserve Capacity: Positive Findings with 15O-Water PET in Patients with Negative 99mTc-HMPAO SPECT Findings
  • Responsible Radiomics Research for Faster Clinical Translation
  • Targeted Molecular Radiotherapy of Pediatric Solid Tumors Using a Radioiodinated Alkyl-Phospholipid Ether Analog
  • Clinical Quantification of Myocardial Blood Flow Using PET: Joint Position Paper of the SNMMI Cardiovascular Council and the ASNC
  • Impact of Endothelial 18-kDa Translocator Protein on the Quantification of 18F-DPA-714
  • 68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning
  • 68Ga-NOTA-Functionalized Ubiquicidin: Cytotoxicity, Biodistribution, Radiation Dosimetry, and First-in-Human PET/CT Imaging of Infections
  • Clinical Molecular Imaging of Chemokine Receptor CXCR4 Expression in Atherosclerotic Plaque Using 68Ga-Pentixafor PET: Correlation with Cardiovascular Risk Factors and Calcified Plaque Burden
  • Test–Retest Reliability of the SERT Imaging Agent 11C-HOMADAM in Healthy Humans
  • Selective Tau Imaging: Der Stand der Dinge
  • Evaluation of the Lysophosphatidic Acid Receptor Type 1 Radioligand 11C-BMT-136088 for Lung Imaging in Rhesus Monkeys
  • Preclinical Development of CD38-Targeted [89Zr]Zr-DFO-Daratumumab for Imaging Multiple Myeloma
  • Why Targeting PSMA Is a Game Changer in the Management of Prostate Cancer
  • 68Ga-Pentixafor PET/CT Imaging of Chemokine Receptor CXCR4 in Chronic Infection of the Bone: First Insights
  • Improved Estrogen Receptor Assessment by PET Using the Novel Radiotracer 18F-4FMFES in Estrogen Receptor–Positive Breast Cancer Patients: An Ongoing Phase II Clinical Trial
  • The Impact of Adding Sentinel Node Biopsy to Extended Pelvic Lymph Node Dissection on Biochemical Recurrence in Prostate Cancer Patients Treated with Robot-Assisted Radical Prostatectomy
  • Dynamic 18F-FDG PET Lymphography for In Vivo Identification of Lymph Node Metastases in Murine Melanoma
  • Immunohistochemical Validation of PSMA Expression Measured by 68Ga-PSMA PET/CT in Primary Prostate Cancer
  • Long-Acting Somatostatin Analog Therapy Differentially Alters 68Ga-DOTATATE Uptake in Normal Tissues Compared with Primary Tumors and Metastatic Lesions
  • Prognostic Value of 123I-BMIPP SPECT in Patients with Nonischemic Heart Failure with Preserved Ejection Fraction
  • Determination of the Heart-to-Mediastinum Ratio of 123I-MIBG Uptake Using Dual-Isotope (123I-MIBG/99mTc-Tetrofosmin) Multipinhole Cadmium-Zinc-Telluride SPECT in Patients with Heart Failure
  • In Vivo Imaging of Pro- and Antitumoral Cellular Components of the Tumor Microenvironment
  • PSMA PET: Transformational Change in Prostate Cancer Management?
  • 18F-Flortaucipir PET/MRI Correlations in Nonamnestic and Amnestic Variants of Alzheimer Disease
  • Early Evaluation of Response Using 18F-FDG PET Influences Management in Gastrointestinal Stromal Tumor Patients Treated with Neoadjuvant Imatinib
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • This Month in JNM
  • This Month in JNM
  • This Month in JNM
Show more This Month in JNM

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire